DAEWOONG PHARMACEUTICAL CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 111,900 KRW | +0.18% |
|
+1.27% | -4.20% |
| Apr. 24 | Korean Sugar Imports Plunge 14% as Diabetes Cases Surge | MT |
| Apr. 12 | AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd | CI |
Chart calendar Daewoong Pharmaceutical Co., Ltd
2bb216923f50ee0d5a7928d259.OQoainKyVE1j8gwHFHkB6E0HbqKEl8v-GN6rTPzw2T8.UXkqvwP7GwQ2mEdfcSxUuzx3O8rp-PqEKYnkdLPJiGAPM0D7AMIePwC4ew~ae88ace0164de72e178b706527ec3557
Upcoming events on Daewoong Pharmaceutical Co., Ltd
Past events on Daewoong Pharmaceutical Co., Ltd
| 2024-03-27 | Annual General Meeting |
| 2024-02-06 03:50 am | Q4 2023 Earnings Release |
| 2023-11-21 11:30 pm | Investor Meeting |
| 2023-11-01 01:33 am | Q3 2023 Earnings Release |
| 2023-10-23 | CPhI Worldwide Conference |
| 2023-05-14 | Q1 2023 Earnings Release |
| 2023-05-08 | Roadshow - Day 2 |
| 2023-05-07 | Roadshow - Day 1 |
| 2023-03-20 | Q4 2022 Earnings Release |
| 2022-11-15 05:18 am | Q3 2022 Earnings Release |
| 2022-08-15 | Interim 2022 Earnings Release |
| 2022-05-15 | Q1 2022 Earnings Release |
| 2022-02-21 09:00 am | FY 2021 Earnings Release |
| 2021-08-16 | Interim 2021 Earnings Release |
| 2021-05-16 | Q1 2021 Earnings Release |
| 2021-02-14 | FY 2020 Earnings Release |
| 2020-03-29 | FY 2019 Earnings Release |
| 2019-11-13 | Q3 2019 Earnings Release |
| 2019-05-14 | Q1 2019 Earnings Release |
| 2019-01-21 | World Stem Cell Summit |
Past dividends on Daewoong Pharmaceutical Co., Ltd
| 2023-12-26 | Annual 600 KRW |
| 2022-12-27 | Annual 600 KRW |
| 2021-12-28 | Annual 600 KRW |
| 2020-12-28 | Annual 600 KRW |
| 2019-12-26 | Annual 600 KRW |
| 2018-12-26 | Annual 600 KRW |
| 2017-12-26 | Annual 600 KRW |
| 2016-12-27 | Annual 600 KRW |
| 2015-12-28 | Annual 700 KRW |
| 2014-12-28 | Annual 700 KRW |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Billions KRW | Released Forecast Spread | 1 005 999 0.61% | 945 956 -1.19% | 1 055 1 053 0.25% | 1 161 1 176 -1.29% | 1 222 1 225 -0.25% | 1 289 |
|
EBITDA Billions KRW | Released Forecast Spread | 62,4 70,8 -11.87% | 45,6 45,8 -0.32% | 128 129 -0.72% | 138 150 -7.8% | 169 166 1.8% | 183 |
|
EBIT Billions KRW | Released Forecast Spread | 31,4 35,2 -10.53% | 12,6 10,8 17.45% | 95,5 92,2 3.55% | 106 116 -8.62% | 133 132 0.71% | 145 |
|
Earnings before Tax (EBT) Billions KRW | Released Forecast Spread | 16,4 27,3 -39.79% | -7,78 -8,74 10.93% | 31,7 29,2 8.76% | 85,7 103 -16.58% | 112 109 2.1% | 110 |
|
Net income Billions KRW | Released Forecast Spread | 20,2 20,8 -2.75% | 3,14 -9,85 131.87% | 40,5 19,1 111.45% | 80,1 81,2 -1.26% | 112 84,3 32.26% | 79,3 |
|
EPS KRW | Released Forecast Spread | 1 960 1 805 8.6% | 294 -540 154.45% | 3 253 1 672 94.51% | 4 387 7 046 -37.73% | 9 760 7 308 33.56% | 6 856 |
| Announcement Date | 13/02/20 | 15/02/21 | 15/02/22 | 15/02/23 | 05/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Billions KRW | Released Forecast Spread | 275 275 -0.04% | 272 275 -0.85% | 294 293 0.31% | 301 300 0.53% | 294 309 -4.9% | 292 302 -3.27% | 307 323 -4.85% | 303 322 -5.97% | 320 315 1.49% | 297 304 -2.45% | 332 | 333 | 355 | 335 |
|
EBITDA Billions KRW | Released Forecast Spread | 41,4 40,4 2.57% | 38,2 43,1 -11.16% | 23,4 43,3 -45.78% | 39,3 33,2 18.23% | 45,0 45,2 -0.41% | 43,2 39,9 8.2% | 41,6 35,0 18.94% | 42,8 | 46,3 | 46,7 | 46,8 | |||
|
EBIT Billions KRW | Released Forecast Spread | 24,7 22,5 9.8% | 26,8 24,6 8.69% | 33,6 31,1 7.9% | 30,3 33,5 -9.4% | 15,3 25,4 -39.73% | 31,0 27,4 13.25% | 36,2 35,9 0.71% | 34,2 33,0 3.63% | 32,0 30,2 6.22% | 31,2 34,3 -9.04% | 40,6 | 38,5 | 37,4 | 35,3 |
|
Earnings before Tax (EBT) Billions KRW | Released Forecast Spread | 20,3 20,1 0.67% | 24,2 20,2 19.64% | 27,7 26,7 3.8% | 29,0 29,2 -0.78% | 4,90 19,7 -75.08% | 27,2 29,5 -7.92% | 32,0 39,3 -18.61% | 26,1 30,7 -14.94% | 26,4 13,1 101.65% | 13,9 28,6 -51.17% | 35,5 | 33,4 | 32,3 | 30,2 |
|
Net income Billions KRW | Released Forecast Spread | 34,9 15,3 128.38% | 17,5 17,4 0.67% | 20,7 26,6 -21.98% | 21,5 21,9 -1.74% | 20,4 19,2 6.39% | 20,5 21,9 -6.3% | 28,8 23,9 20.33% | 19,8 21,2 -6.77% | 42,5 19,4 118.72% | 10,8 23,9 -54.6% | 27,0 | 25,4 | 24,5 | 22,9 |
|
EPS KRW | Released Forecast Spread | 1 832 | |||||||||||||
| Announcement Date | 15/02/22 | 28/04/22 | 28/07/22 | 31/10/22 | 15/02/23 | 03/05/23 | 27/07/23 | 27/10/23 | 05/02/24 | 29/04/24 | - | - | - | - |
More events
Past sector events for Daewoong Pharmaceutical Co., Ltd
| 2024-05-02 10:34 am | PROCTER & GAMBLE HEALTH LIMITED: Q3 2024 Earnings Release |
| 2024-05-02 07:09 am | AJANTA PHARMA LIMITED: Q4 2024 Earnings Release |
| 2024-04-29 | SINOTHERAPEUTICS INC.: Q4 2023 Earnings Release |
| 2024-04-29 | KUNMING LONGJIN PHARMACEUTICAL CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-29 | OTSUKA HOLDINGS CO., LTD.: Q1 2024 Earnings Release |
| 2024-04-29 | YIFAN PHARMACEUTICAL CO., LTD.: Q1 2024 Earnings Release |
| 2024-04-29 | BORYUNG CORPORATION: Q1 2024 Earnings Release |
| 2024-04-29 | HANMI PHARM. CO., LTD.: Q1 2024 Earnings Release |
| 2024-04-28 | SINOTHERAPEUTICS INC.: Q1 2024 Earnings Release |
| 2024-04-28 | SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- A069620 Stock
- Calendar Daewoong Pharmaceutical Co., Ltd
